

LIVING WITH LUPUS IN 2020

COUNTRY LEVEL DATA

Poland



DATA FOR: Poland

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

COUNTRY: F	Poland				
		DEM	OGRAPHICS:		
	<u>Poland</u>	<u>EUROPE</u>	<u>Age</u>	<u>Poland</u>	EUROPE
Total number of responses	120	4375	Up to 25	9.2%	6.4%
			26 to 35	29.2%	17.9%
<u>Gender</u>	<u>Poland</u>	<u>EUROPE</u>	36 to 45	40.8%	27.4%
Man	0.8%	3.7%	46 to 55	11.7%	26.6%
Woman	98.3%	95.6%	56 to 65	7.5%	14.8%
Other / prefer not to answer	0.8%	0.7%	above 65	0.8%	5.1%
Total	100.0%	100.0%	NA	0.8%	1.8%
			Grand Total	100.0%	100.0%
		DI	AGNOSIS		
<u>Diagnosis</u>	<u>Poland</u>	<u>EUROPE</u>	Time to Diagnosis	<u>Poland</u>	EUROPE
SLE	95.0%	94.4%	Within the year	27.2%	26.5%
Child onset SLE	5.0%	5.6%	1 year	24.6%	21.1%
Grand Total	100.0%	100.0%	2 years	12.3%	11.5%
			3 years	5.3%	5.7%
Prior Diagnosis received before "Lupus"	<u>Poland</u>	<u>EUROPE</u>	4 years	6.1%	4.6%
None	49.2%	53.7%	5 years	0.0%	4.4%
UCTD/MCTD	16.7%	6.7%	6 years	3.5%	2.9%
Sjogren	2.5%	4.7%	7 years	2.6%	2.7%
APS	2.5%	2.4%	8 years	4.4%	2.4%
Other Autoimmune or Rheumatic	20.0%	13.8%	9 years	4.4%	2.3%
Fibromyalgia	3.3%	5.8%	10 to 20 years	7.0%	10.4%
Psychologic or mental disorder	7.5%	8.9%	More than 20 years	2.6%	5.5%
Other prior diagnosis	17.5%	16.5%	Grand Total	100.0%	100.0%
n=	118	4,275	n=	114	4,154



DATA FOR: Poland

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

		IMPACT ON STUD	IES & CAREER		
Education level	<u>Poland</u>	<u>EUROPE</u>	Employment level	<u>Poland</u>	<u>EUROPE</u>
Basic	0.0%	3.7%	Employed full time	44.9%	34.6%
Secundary	44.4%	53.9%	Employed part time	5.9%	16.5%
Academic	55.6%	42.5%	Self-employed full time	5.1%	3.0%
n=	117	4,150	Self-employed part time	0.8%	2.4%
			Looking for employment	5.9%	5.1%
Economic profile	<u>Poland</u>	<u>EUROPE</u>	Stopped work for medical reason	19.5%	14.7%
No difficulties paying all bills	45.0%	46.9%	Retired	2.5%	11.6%
Occasional difficulties paying all bills.	26.7%	26.8%	Student	5.9%	4.0%
Often difficulties paying all bills	13.3%	10.4%	No paid employment / Full time home	5.1%	4.7%
Always difficulty paying all bills	6.7%	7.1%	Other / prefer not to answer	4.2%	3.5%
Did not respond	8.3%	8.9%			
n=	120	4375	n=	118	4247
IMPACT ON STUDIES	<u>Poland</u>	<u>EUROPE</u>	IMPACT ON CAREER	<u>Poland</u>	EUROPE
Chose more relevant studies	7.6%	3.1%	No impact	36.9%	32.5%
could not do what they wanted	16.9%	11.1%	Changed career/ job	13.5%	13.5%
needed special support and received it	5.1%	4.6%	moved to Flexible hours	9.0%	8.1%
needed support but did NOT receive it	6.8%	2.9%	Reduced Work Schedule	16.2%	18.5%
Overall negative effect	9.3%	13.5%	Stopped work, gets social allowances	17.1%	18.5%
Overall positive effect	0.8%	1.4%	Missed promotion opportunities	3.6%	9.5%
No impact	61.9%	69.8%	Employment was terminated	15.3%	8.4%
			Other negative impact	15.3%	20.8%
n=	118	4240	Other positive impact	1.8%	1.8%
			Overall had negative impact	51.4%	57.9%
			n=	111	4024



DATA FOR: Poland

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

			INADACT ON SO	OCIAL / FAMILY		
			IIVIPACI ON 30	CIAL / FAIVILT		
Civil status		Poland	EUROPE	Have children	Poland	EUROPE
Child/young with family		4.5%	4.5%	None	36.4%	32.8%
Single		15.3%	17.4%	One child	22.9%	23.8%
Married / with partner		72.1%	66.9%	2 or more children	36.4%	38.9%
Divorced		5.4%	9.2%	Child/young living with family	4.2%	4.5%
Widowed		2.7%	2.0%			
	n=	111	4206	n=	118	4288
Would have liked more children		<u>Poland</u>	<u>EUROPE</u>	Faced Misscariages	<u>Poland</u>	EUROPE
A. Yes		34.2%	37.6%	A. One miscarriage	15.3%	18.4%
B. No		38.7%	37.7%	B. Some miscarriages	8.1%	8.5%
C. don't know / prefer not to answer		27.0%	24.7%	C. Many miscarriages	0.9%	2.9%
				D. No miscarriage	75.7%	70.2%
n (women	only) =	111	3,645	n (women only) =	111	3,756
Difficulty to cope with Daily activities		<u>Poland</u>	<u>EUROPE</u>	More or less active than others same age	<u>Poland</u>	<u>EUROPE</u>
No Problem at all 1		24.6%	16.2%	Less active due to lupus	72.0%	72.6%
2		39.0%	32.3%	Equally active	20.3%	15.6%
3		25.4%	34.3%	More active due to lupus	2.5%	3.6%
4		9.3%	15.4%	I don't know	5.1%	8.1%
Fully Unable 5		1.7%	1.8%			
	n=	118	4226	n=	118	4212
Impact on Sexual/emotional life		<u>Poland</u>	<u>EUROPE</u>	Negative Impact on couple	<u>Poland</u>	EUROPE
Negative impact		39.8%	38.2%	It created tensions	33.7%	33.2%
Mixed Positive and negative		36.4%	36.2%	It is difficult for me	62.8%	68.4%
No significant impact		23.7%	23.9%	It is difficult for my partner	20.9%	26.7%
Positive impact		0.0%	1.6%	I am concerned for my couple	19.8%	13.2%
				Our relationship ended	20.9%	16.6%
	n=	118	4,204	n=	86	2875



DATA FOR: Poland

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DISEASE ACTIVITY							
Lupus was under control past 3 mont	h <u>s</u>	<u>Poland</u>	<u>EUROPE</u>	Number of symptoms (list of 23)	oland	EUROPE	
Yes		71%	72%	1	2.6%	1.6%	
No		29%	28%	2	4.3%	2.1%	
				3	5.1%	4.4%	
	n=	120	4347	4	5.1%	5.9%	
				5	4.3%	6.1%	
				6	11.1%	8.5%	
		<u>Poland</u>	<u>EUROPE</u>	7	6.8%	9.3%	
Average nr of symptoms (list of 23)		8.4	8.8	8	9.4%	10.4%	
	n=	117	4197		11.1%	10.1%	
				10	8.5%	9.3%	
					12.0%	8.3%	
		<u>Poland</u>	<u>EUROPE</u>	12	7.7%	7.0%	
Median number of symptoms		9	9	13	3.4%	5.8%	
	n=	117	4197	14	3.4%	4.4%	
				15	1.7%	2.7%	
				16	2.6%	2.1%	
				17	0.9%	1.1%	
				18	0.0%	0.4%	
				19	0.0%	0.3%	
				20	0.0%	0.0%	
				n=	117	4197	



DATA FOR: Poland

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

Symptoms or Features experienced / Most bothersome

	<u>Poland</u>			EURC)PE
	Regularly	Top 3 most		Regularly	Top 3 most
Patient reported Symptoms or features	<u>experience</u>	<u>bothersome</u>	Patient reported Symptoms or features	<u>experience</u>	<u>bothersome</u>
A. Rash	26%	6%	A. Rash	40%	9%
B. Sun sensitivity	67%	18%	B. Sun sensitivity	69%	23%
C. Mouth ulcers	29%	4%	C. Mouth ulcers	35%	3%
D. Dryness in the mouth or eyes	44%	7%	D. Dryness in the mouth or eyes	55%	9%
E. Dryness of the skin	64%	6%	E. Dryness of the skin	57%	4%
F. Hair loss	68%	21%	F. Hair loss	53%	14%
G. Pain / swelling in joints	68%	56%	G. Pain / swelling in joints	77%	49%
H. Jaccoud (hand deformation) or tendons a	6%	3%	H. Jaccoud (hand deformation) or tendor	14%	4%
I. Muscle Pain/Weakness	53%	21%	I. Muscle Pain/Weakness	68%	33%
J. Headaches or migraine	60%	24%	J. Headaches or migraine	51%	17%
K. Fatigue and weakness	88%	50%	K. Fatigue and weakness	85%	55%
L. Flu-like symptoms/Fevers	25%	4%	L. Flu-like symptoms/Fevers	28%	4%
M. Shortness of breath	17%	4%	M. Shortness of breath	32%	6%
N. Depression or Anxiety	39%	11%	N. Depression or Anxiety	44%	17%
O. Haematologic problems incl. anemia	33%	6%	O. Haematologic problems incl. anemia	27%	4%
P. Poor circulation or Raynauds	38%	8%	P. Poor circulation or Raynauds	45%	8%
Q. Kidney problems	32%	18%	Q. Kidney problems	20%	11%
R. Chest pain	32%	4%	R. Chest pain	24%	4%
S. High Blood pressure	24%	6%	S. High Blood pressure	23%	4%
T. Stroke, mini-stroke, Blood clots	6%	3%	T. Stroke, mini-stroke, Blood clots	9%	4%
U. Osteoporosis	22%	4%	U. Osteoporosis	19%	5%
n=	120	113	n=	4375	4084



DATA FOR: Poland

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

MEDICATION							
Average number of medication (from list	<u>Poland</u>	<u>EUROPE</u>	Median number of medication (from	<u>Poland</u>	EUROPE		
-		F 2	· · · · · · · · · · · · · · · · · · ·	6	F		
<u>of 16)</u>	5.8	5.2	<u>list of 16)</u>	6	5		
n=	= 113	4099	n=	113	4099		
Number of medications (list of 16)	<u>Poland</u>	<u>EUROPE</u>	% using given medication type:	<u>Poland</u>	<u>EUROPE</u>		
1	L 3.5%	5.4%	Non Steroids Anti-Inflammatory	27.4%	32.9%		
2	9.7%	9.0%	Antimalarials	76.1%	75.0%		
3	3 4.4%	12.5%	Oral Steroids	67.3%	52.4%		
4	15.9%	14.1%	Immunosuppressants	44.2%	39.8%		
5	5 15.0%	14.8%	Biologics	3.5%	10.9%		
ϵ	8.8%	13.9%	Painkillers	46.9%	50.1%		
7	7 11.5%	11.8%	Antidepressant	9.7%	17.0%		
8	3 15.9%	9.0%	Anxiolytic	4.4%	11.7%		
g	8.0%	5.1%	Anticoagulants	17.7%	16.6%		
10	4.4%	2.5%	Thyroid medication	21.2%	14.8%		
11	1.8%	1.1%	Blood circulation and heart	23.0%	23.3%		
12	0.9%	0.4%	Stomach protection	57.5%	47.0%		
13	0.0%	0.2%	Statins	6.2%	5.9%		
			Calcium	47.8%	29.7%		
n=	= 113	4099	Vitamin D	84.1%	68.4%		
			Vitamins (excl.D) / mineral complements		25.4%		



DATA FOR: Poland

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

ACCESS / Quality of life (scale of 1 to 5)

I have appropriate access to	<u>Po</u>	<u>land</u>	<u>EUROPE</u>	HrQoL dimensions	<u>Poland</u>	<u>EUROPE</u>
Average scores (1 Fully dis	sagree - 5 fully	agree)		AVERAGE SCORES (1=FULLY ABLE,	5= FULLY UNA	ABLE)
Experienced lupus doctors		3.29	3.81	Mobility	2.14	2.22
Multidisciplinary team		2.47	3.28	Self care	1.64	1.71
Specialised nurses that know lupus		2.09	2.92	Daily Activities	2.25	2.54
Prescribed medication		3.25	4.08	Pain or discomfort	3.12	3.14
Affordable treatments		2.89	3.77	Anxiety or depression	3.28	2.96
Social support and benefits		2.26	2.78	Average	2.48	2.51
Physiotherapy, Rehab, Occupational Tl	nera	2.27	2.77			
Professional psychological support		2.43	2.68			
n	min	86	3126	n min	116	4196
n r	max	101	3842	n max	118	4240
Worry about lupus progressing?	<u>Po</u>	land	<u>EUROPE</u>			
Very Low (1-2)		2.7%	3.6%			
Low (3-4)	13	L.7%	9.3%			
Mid (5-6)	14	1.4%	24.5%			
High (7-8)	36	5.0%	41.0%			
Very high (9-10)	35	5.1%	21.6%			
	n=	111	4042			



DATA FOR: Poland

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

Impact of lupus not being under control over past 3 months

	% of Health Related	d OoL Maintaine	ed vs 100% = FULL HEALTH/ABILITY TO PERFORM		
	<u>Poland</u>				PE
	<u>lupus under</u>	not under		lupus under	<u>not under</u>
	control	<u>control</u>		<u>control</u>	<u>control</u>
Mobility	76%	60%	Mobility	73%	59%
Self care	89%	73%	Self care	86%	73%
Daily Activities	73%	59%	Daily Activities	66%	51%
Pain or discomfort	52%	35%	Pain or discomfort	51%	35%
Anxiety or depression	47%	33%	Anxiety or depression	54%	44%
Average	67%	52%	Average	66%	52%
n mi	n 83	33	n min	3011	1179
n ma	x 84	34	n max	3042	1194
	Polan	d		EURO	PE
	lupus under	not under	More or less active than others of same	lupus under	not under
More or less active than others of same age	control	control	age	control	control
Less active due to lupus	67.9%	82.4%	Less active due to lupus	68.6%	83.0%
Equally active	25.0%	8.8%	Equally active	18.8%	7.6%
More active due to lupus	2.4%	2.9%	More active due to lupus	4.0%	2.7%
I don't know	4.8%	5.9%	I don't know	8.7%	6.7%
n	= 84	34	n=	3018	1189
	Polan	d		EURO	PE
	lupus under	not under		lupus under	not under
Impact on Sexual/emotional life	control	control	Impact on Sexual/emotional life	control	control
Negative impact	33.3%	55.9%	Negative impact	34.0%	49.0%
Mixed + and -	36.9%	35.3%	Mixed + and -	36.4%	35.7%
No significant impact	29.8%	8.8%	No significant impact	27.8%	14.1%
Positive impact	0.0%	0.0%	Positive impact	1.8%	1.2%
n	= 84	34	n=	3018	1181



DATA FOR: Poland

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

IMPACT OF A PROMPT DIAGNOSIS

% of Health Related QoL Maintained vs 100% = FULL HEALTH/ABILITY TO PERFORM

	<u>Pola</u>	<u>nd</u>		EURO	<u>OPE</u>
		<u>Diagnosed</u>		<u>Diagnosed</u>	<u>Diagnosed</u>
	<u>Diagnosed</u>	after more		within 2	after more
	within 2 years	than 5 years		<u>years</u>	than 5 years
Mobility	77%	63%	Mobility	75%	62%
Self care	90%	76%	Self care	86%	76%
Daily Activities	79%	50%	Daily Activities	67%	53%
Pain or discomfort	57%	32%	Pain or discomfort	52%	39%
Anxiety or depression	48%	32%	Anxiety or depression	52%	49%
Average	70%	50%	Average	66%	56%
Difference		-20%	Difference		-10%
of which - explained by age (*)		-1%	of which - explained by age		-3%
n min	57	26	n min	1926	1239
n max	59	28	n max	1951	1249
average age:	36.2	40.2		41.2	49.0


^(*) in our overall study, we found that from age 28 to age 63 HrQOL drops from 69.1% to 56.0% i.e. 3.7% per decade





DATA FOR: Poland


Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: 0












DATA FOR: Poland

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: 0







Living with lupus in 2020 - Country level data

DATA FOR: 0

For full text european analysis, please refer to:

Cornet A, Andersen J, Myllys K, et al. Living with systemic lupus erythematosus in 2020: a European patient survey. Lupus Science & Medicine 2021;8:e000469. doi:10.1136/lupus-2020-000469

For more informatioin, contact: secretariat@lupus-europe.org